Sign in with Google. Opens in new tab
ENTITY
Biogen Inc

Biogen Inc (BIIB US)

134
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bullishBiogen Inc
03 Mar 2022 02:10

Biogen Inc.: Financial & Price Forecasts

Biogen witnessed a 4% year over year drop in its top-line in the last quarter as Tecifidera revenue continued to erode in the U.S. due to generic...

Logo
93 Views
Share
bullishS&P 500 INDEX
01 Feb 2022 17:45

Not Out Of The Woods; SPX Back Above The 200-Day MA; Growth Catching A Bid; Buying Energy, Biotech

The short-term bullish reversal that we referenced last week is officially underway now that the S&P 500 has reclaimed its 200-day MA, but we are...

Logo
285 Views
Share
31 Jan 2022 17:32

Samsung Biologics: Rights Offering of 3 Trillion Won to Acquire Remaining Stake in Samsung Bioepsis

Despite the long-term positive prospects of consolidating results from Samsung Bioepsis, we believe the acquisition price was a bit too high at...

Logo
486 Views
Share
20 Jan 2022 15:09

Samsung Biologics (207940 KS): Well-Positioned to Leap Forward Without Biogen Deal

Without Biogen acquisition deal, Samsung Biologics is well-positioned for strong growth on the back of its massive capacity expansion plan amid a...

Logo
369 Views
Share
05 Jan 2022 16:43

Vigil Neuroscience (VIGL US) IPO: Early-Stage First-Of-Its-Class Pipeline Makes It a Risky Bet

The company plans to raise $112 million through its IPO. Vigil is a clinical-stage biotech company, whose lead drug candidate has just entered into...

Logo
403 Views
Share
x